Skip to content
Insights Hub
Event

ESC Congress 2026: AI in the chest pain pathway

Originally published on explorishealth.com

24 min · Digital Health Symposium, ESC Congress 2026, Munich

At the Digital Health Symposium at ESC 2026 in Munich, Prof. Hans-Peter Brunner-La Rocca presented how multi-marker AI can improve the assessment of obstructive coronary artery disease (CAD) and patient selection for downstream testing.

Ruling out acute coronary syndrome does not rule out underlying CAD. Yet 70–80% of patients presenting to chest pain units are troponin-negative, which leaves an important clinical question open: who is actually at risk of obstructive CAD?

The current ESC risk factor-weighted clinical likelihood assessment has important limitations. It is based on a small number of clinical parameters and strongly influenced by symptom classification. As a result, it may underestimate risk in atypical presentations while directing many intermediate-risk patients towards CCTA.

Cardio Explorer® takes a multi-marker AI approach. It combines 32 routinely available clinical parameters to capture complex, non-linear relationships associated with obstructive CAD. In the presented validation, the model achieved an AUC of 0.878.

The value extends beyond prediction. The analysis showed that Cardio Explorer distributes patients more selectively across diagnostic probability thresholds, which could support more targeted use of CCTA, functional testing and invasive angiography.

The key message from Munich: the next step for cardiovascular AI is not simply better prediction, but turning more individualized risk assessment into better clinical decisions and more efficient care pathways – and, with them, better hospital economics.

Interested in how Cardio Explorer® applies to your coronary pathway? Our team is happy to walk you through the platform and the evidence behind it.